Author Archives: admin


Why the Cumulina Mouse Is Headed to the Smithsonian | At the Smithsonian – Smithsonian Magazine

A taxidermied Cumulina holds a block of toy cheese. Cade Martin

It was a sad day in the department of anatomy and reproductive biology at the University of Hawaii, Manoa. On May 5, 2000, an elderly mouse named Cumulina, whose birth had captured international headlines, died of natural causes. She was special, Ryuzo Yanagimachi, the laboratorys principal investigator, said at the time.

Born on October 3, 1997, Cumulina was the first successfully cloned mouse and the second mammal ever cloned from an adult cell. She was also the forerunner of a technique that would establish once and for all that the long-awaited possibility of cloning animals could be readily accomplished. Her birth came just 15 months after the birth of Dolly the Sheep, the worlds first mammal cloned from an adult cell, had shocked scientists and the public alike, raising ethical questions in some quarters about the science fiction-like possibility of human cloning while also inspiring worldwide hopes of coming breakthroughs in biomedicine.

Dollys success proved complicated, though; of the 277 embryos her stewards at the Roslin Institute in Edinburgh cloned as part of the experiment, Dolly was the only one born. The teams method involved removing the nucleus from a Scottish Blackface sheeps egg cell and electroshocking it with a mammary gland cell from a Finn Dorset sheep to enable the two to fuse. They then implanted this unusual egg cellwhich contained a full complement of DNA but had never been fertilizedinto a ewe, who brought it to term.

The Roslin scientists went on to clone more lambs, and in 1997 they cloned the first transgenic mammals from adult cells.But in the meantime, Teruhiko Wakayama, one of Yanagimachis postdoctoral researchers in Hawaii, came up with another idea.

Wakayama had been galvanized by news of Dollys birth, and spent free time in the lab to try to create a mouse clone. He removed nuclei from egg cells and replaced them by injecting nuclei taken from adult mouse cumulus cells, which normally play a role in egg maturation. He then implanted these special eggs into surrogate female mice to see whether they would successfully give birth.

After a number of failed attempts in the fall of 1997, Wakayama and Yanagimachi produced a stunning result: a healthy female mouse pup. He named her Cumulina, after the cells he had used to create her. Celebrated internationally for his achievement, Wakayama went on to become a professor at the University of Yamanashi in Japan and Yanagimachi founded the Institute for Biogenesis Research at the University of Hawaii.

In the year after Cumulinas birth, Wakayama and Yanagimachi made 84 more cloned mice, putting to rest lingering skepticism over whether cloning was practicable. Wakayamas method proved more efficient than the one the Roslin scientists had used to produce Dolly. Cumulina truly represented a breakthrough in the cloning technique, says W. Steven Ward, director of the University of Hawaiis Institute for Biogenesis Research.

So far scientists have cloned more than 20 types of animals. Mice created through the nuclear transfer method that was used to make Cumulina are now the most abundant cloned animals in the world. Nonetheless, some of the more spectacular scenarios from the 1990s about cloning have not come true. Researchers still have not managed, for example, to replace a dying persons failing organ with a new one generated from cloned cells. But the early work that produced Dolly, Cumulina and other cloned animals has contributed to advances in stem-cell technologies that are now helping scientists explore regenerative medicine, investigate the underpinnings of diseases ranging from leukemia to diabetes and research new pharmaceuticals.

Laboratory mice typically dont reach old age, but Yanagimachis crew made every effort to ensure Cumulinas longevity. They even threw birthday parties for her. She was a pretty pampered mouse, says Kristen Frederick-Frost, curator of modern science at the Smithsonian's National Museum of American History.

Cumulina lived well past age 2, the equivalent of over 90 in human years. After she died, Yanagimachi preserved her in a freezer until a local high school teacher offered to taxidermy her body. The teacher posed Cumulina holding a block of fake cheese, and the stuffed mouse sat on display in Yanagimachis lab for a couple of years before being relegated to a closet. In 2004, she barely escaped being washed away in a flood, and has since spent most of her time in storage.

Yanagimachi retired in 2005, and last year, Ward contacted curators at the National Museum of American History. The decision to accept Cumulina was a no-brainer, Frederick-Frost says. The collection also includes OncoMouse, the worlds first patented genetically modified animal, who, along with his successors, was used for cancer research.

Rachel Nuwer | | READ MORE

Rachel Nuwer is a freelance science writer based in Brooklyn.

Recommended Videos

Read the original here:
Why the Cumulina Mouse Is Headed to the Smithsonian | At the Smithsonian - Smithsonian Magazine

Houston cell therapy company prepares to IPO, move into new facility – InnovationMap

Using technology to solve big problems has always been Kelly Pracht's career, but she never thought she'd be able use her skills for the sports world she's a lifelong fan of.

After spending nearly 20 years at HP Inc. in various leadership roles and across technology, Pract was watching a baseball game when something clicked for her. Baseball and its endless data points and metrics wasn't serving up analytics that the fans cared about. Teams and leagues had their own metic priorities, but fans just want to engage with the game, their team, and the players.

"I saw a gap in how we handle the data coming from the field and how that can impact the fan and nobody was getting it right," Pracht, co-founder and CEO of nVenue, tells InnovationMap. "I saw technologists coming up with the most nonsensical solutions. For fans like me, coming from my crazy sports family from West Texas where my dad was a coach, I knew that these solutions were a huge miss."

She gives the example of a wearable technology for the viewer at home that can feel what it feels like for the players on the field who get hit. Pracht says it seems like companies were trying to fit technology into the sport, rather than thinking of what the fans really wanted.

She had the idea for a data-driven fan tool in 2017 and nVenue was born. She started building out the code and the team started testing it out at Astros games at Minute Maid.

"What great years to develop this platform. It was fun these were not boring baseball games," Pracht says. The Astros have won their division four out of the past five years, including winning the World Series in 2017.

Kelly Pracht is the CEO and co-founder of nVenue. Photo courtesy of nVenue

At first, nVenue was using historical data, and that in itself was impressive. But then, Pracht and her team decided to take it live. After building its proprietary analytics platform, nVenue could use data to make predictions in real time.

"We spent over a year all of 2019 mastering timing and putting it into a platform," Pracht says, explaining how they built out the artificial intelligence and designed an app for fans to interface with. "We wanted to be able to predict and play. We had over 180 people during the 2019 World Series and playoffs."

The app and algorithm were good and nVenue expanded into football. Then, the pandemic hit and sports halted completely. Pracht says they pivoted to a B2B model but wasn't seeing any real opportunities for the platform until the 2021 Comcast NBCUniversal SportsTech Accelerator.

"In kind of a last-ditch effort, we applied to the NBC Comcast accelerator somewhere around August or September of 2020," Pracht says, explaining that she wasn't seeing a sustainable business so it was get into the program or close up shop. "And we got in. They just resonated with everything we said we found our people."

The accelerator gave nVenue the jumpstart it needed, and as sports returned, the company found its momentum again. Now, the company is headquartered in Dallas with 14 employees all over and three including Pracht in Houston. The company has raised its $3.5 million seed round co-led by KB Partners and Corazon Capital and plans to raise a Series A next year.

After a few broadcasts last season, opportunity came knocking by way of Apple TV and Houston-based TV Graphics. The companies collaborated on a deal and, two weeks before the 2022 season started, nVenue got the greenlight to have onscreen analytics on Apple TV broadcasts.

"In under two weeks we structured the deal, convinced them it worked, pulled together every bit of testing we could by then we only had one week of pre-season games to test and we pulled it off," Pracht says.

The technology has tons of potential when it comes to sports betting, which is a growing business across the country. Pracht says nVenue isn't looking to compete with the providers on the scene, but instead work with them as an analytics tool.

"We broke down the market down to microbets or in-the-moment bets that are going to happen annually by 2025 it's 156 billion microbets a year, which turns out to be 3 billion a week," Pracht says.

She adds that new technologies in the streaming world like no-delay, latency streaming is only going to make the sports betting world more lucrative, and nVenue will be right there to ride that wave.

More here:
Houston cell therapy company prepares to IPO, move into new facility - InnovationMap

Rheumatoid Arthritis Stem Cell Therapy Market Growth: 2022, Observing High Industry Demand and Business Trends Carbon Valley Farmer and Miner -…

The latest release titled Rheumatoid Arthritis Stem Cell Therapy Market Research Report 2022-2028 (by Product Type, End-User / Application, and Regions / Countries) provides an in-depth assessment of the Rheumatoid Arthritis Stem Cell Therapy including key market trends, upcoming technologies, industry drivers, challenges, regulatory policies, key players company profiles, and strategies. Global Rheumatoid Arthritis Stem Cell Therapy Market study with 100+ market data Tables, Pie Chat, Graphs & Figures is now released. The report presents a complete assessment of the Market covering future trends, current growth factors, attentive opinions, facts, and industry-validated market data forecast until 2028.

A sample report can be viewed by visiting (Use Corporate eMail ID to Get Higher Priority) at: https://www.stratagemmarketinsights.com/sample/42901

Global Rheumatoid Arthritis Stem Cell Therapy Market and Competitive Analysis:

Know your current market situation! Not only an important element for new products but also for current products given the ever-changing market dynamics. The study allows marketers to stay in touch with current consumer trends and segments where they can face a rapid market share drop. Discover who you really compete against in the marketplace, with Market Share Analysis know market position, % Market Share, and Segmented Revenue of Rheumatoid Arthritis Stem Cell Therapy Market.

Moreover, it will also include the opportunities available in micro markets for stakeholders to invest, a detailed analysis of the competitive landscape, and product services of key players. Analysis of Rheumatoid Arthritis Stem Cell Therapy companies, key tactics followed by Leading Key Players:

Mesoblast, Roslin Cells, Regeneus, ReNeuron Group, International Stem Cell Corporation, Takeda

Market Segments by Type:

Allogeneic Mesenchymal Stem Cells, Bone Marrow Transplant, Adipose Tissue Stem Cells

Market Segments by Application:

Hospitals, Ambulatory Surgical Centers, Specialty Clinics

The base on geography, the Rheumatoid Arthritis Stem Cell Therapy market has been segmented as follows:

North America includes the United States, Canada, and Mexico Europe includes Germany, France, the UK, Italy, Spain South America includes Colombia, Argentina, Nigeria, and Chile The Asia Pacific includes Japan, China, Korea, India, Saudi Arabia, and Southeast Asia

Get PDF Brochure by Clicking Here: https://www.stratagemmarketinsights.com/sample/42901

The Study Objectives are:

A comprehensive insight into key players operating in the Rheumatoid Arthritis Stem Cell Therapy market and their corresponding data. It includes product portfolio, annual revenue, expenditure on research and development, geographical presence, key developments in recent years, and growth strategies. Regional analysis, which includes insight into the dominant market and corresponding market share. It also includes various socio-economic factors affecting the evolution of the market in the region. The report offers a comprehensive insight into different individuals from value chains such as raw materials suppliers, distributors, and stockholders.

Key Opportunities:

The report examines the key opportunities available in the Rheumatoid Arthritis Stem Cell Therapy market and outlines the factors that are and will be driving the growth of the industry. It considers the previous growth patterns, the growth drivers, and the current and future trends.

Pricing and Forecast

Pricing/subscription always plays an important role in buying decisions; so we have analyzed pricing to determine how customers or businesses evaluate it not just in relation to other product offerings by competitors but also with immediate substitute products. In addition to future sales Separate Chapters on Cost Analysis, Labor*, production*, and Capacity are Covered.

(Note: * if Applicable)

Key Questions Answered:

1. What is the market size and CAGR of the Rheumatoid Arthritis Stem Cell Therapy market during the forecast period? 2. How is the growing demand impacting the growth of Rheumatoid Arthritis Stem Cell Therapy market shares? 3. What is the growing demand of the Rheumatoid Arthritis Stem Cell Therapy market during the forecast period? 4. Who are the leading vendors in the market and what are their market shares? 5. What is the impact of the COVID-19 pandemic on the APAC Rheumatoid Arthritis Stem Cell Therapy market?

Buy This Complete A Business Report:https://www.stratagemmarketinsights.com/cart/42901

Contact Us:

Mr. Shah Stratagem Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Phone: US +12067016702 / UK +4402081334027 / JAPAN +815055391737 Email: sales@stratagemmarketinsights.com

MN

View original post here:
Rheumatoid Arthritis Stem Cell Therapy Market Growth: 2022, Observing High Industry Demand and Business Trends Carbon Valley Farmer and Miner -...

Cell Therapy (Differentiated Cell and Stem Cell) Market Research Report 2022 – Global Forecast to 2027: Investments Help Fuel a Surge in Biotech…

Country

United States of America US Virgin Islands United States Minor Outlying Islands Canada Mexico, United Mexican States Bahamas, Commonwealth of the Cuba, Republic of Dominican Republic Haiti, Republic of Jamaica Afghanistan Albania, People's Socialist Republic of Algeria, People's Democratic Republic of American Samoa Andorra, Principality of Angola, Republic of Anguilla Antarctica (the territory South of 60 deg S) Antigua and Barbuda Argentina, Argentine Republic Armenia Aruba Australia, Commonwealth of Austria, Republic of Azerbaijan, Republic of Bahrain, Kingdom of Bangladesh, People's Republic of Barbados Belarus Belgium, Kingdom of Belize Benin, People's Republic of Bermuda Bhutan, Kingdom of Bolivia, Republic of Bosnia and Herzegovina Botswana, Republic of Bouvet Island (Bouvetoya) Brazil, Federative Republic of British Indian Ocean Territory (Chagos Archipelago) British Virgin Islands Brunei Darussalam Bulgaria, People's Republic of Burkina Faso Burundi, Republic of Cambodia, Kingdom of Cameroon, United Republic of Cape Verde, Republic of Cayman Islands Central African Republic Chad, Republic of Chile, Republic of China, People's Republic of Christmas Island Cocos (Keeling) Islands Colombia, Republic of Comoros, Union of the Congo, Democratic Republic of Congo, People's Republic of Cook Islands Costa Rica, Republic of Cote D'Ivoire, Ivory Coast, Republic of the Cyprus, Republic of Czech Republic Denmark, Kingdom of Djibouti, Republic of Dominica, Commonwealth of Ecuador, Republic of Egypt, Arab Republic of El Salvador, Republic of Equatorial Guinea, Republic of Eritrea Estonia Ethiopia Faeroe Islands Falkland Islands (Malvinas) Fiji, Republic of the Fiji Islands Finland, Republic of France, French Republic French Guiana French Polynesia French Southern Territories Gabon, Gabonese Republic Gambia, Republic of the Georgia Germany Ghana, Republic of Gibraltar Greece, Hellenic Republic Greenland Grenada Guadaloupe Guam Guatemala, Republic of Guinea, Revolutionary People's Rep'c of Guinea-Bissau, Republic of Guyana, Republic of Heard and McDonald Islands Holy See (Vatican City State) Honduras, Republic of Hong Kong, Special Administrative Region of China Hrvatska (Croatia) Hungary, Hungarian People's Republic Iceland, Republic of India, Republic of Indonesia, Republic of Iran, Islamic Republic of Iraq, Republic of Ireland Israel, State of Italy, Italian Republic Japan Jordan, Hashemite Kingdom of Kazakhstan, Republic of Kenya, Republic of Kiribati, Republic of Korea, Democratic People's Republic of Korea, Republic of Kuwait, State of Kyrgyz Republic Lao People's Democratic Republic Latvia Lebanon, Lebanese Republic Lesotho, Kingdom of Liberia, Republic of Libyan Arab Jamahiriya Liechtenstein, Principality of Lithuania Luxembourg, Grand Duchy of Macao, Special Administrative Region of China Macedonia, the former Yugoslav Republic of Madagascar, Republic of Malawi, Republic of Malaysia Maldives, Republic of Mali, Republic of Malta, Republic of Marshall Islands Martinique Mauritania, Islamic Republic of Mauritius Mayotte Micronesia, Federated States of Moldova, Republic of Monaco, Principality of Mongolia, Mongolian People's Republic Montserrat Morocco, Kingdom of Mozambique, People's Republic of Myanmar Namibia Nauru, Republic of Nepal, Kingdom of Netherlands Antilles Netherlands, Kingdom of the New Caledonia New Zealand Nicaragua, Republic of Niger, Republic of the Nigeria, Federal Republic of Niue, Republic of Norfolk Island Northern Mariana Islands Norway, Kingdom of Oman, Sultanate of Pakistan, Islamic Republic of Palau Palestinian Territory, Occupied Panama, Republic of Papua New Guinea Paraguay, Republic of Peru, Republic of Philippines, Republic of the Pitcairn Island Poland, Polish People's Republic Portugal, Portuguese Republic Puerto Rico Qatar, State of Reunion Romania, Socialist Republic of Russian Federation Rwanda, Rwandese Republic Samoa, Independent State of San Marino, Republic of Sao Tome and Principe, Democratic Republic of Saudi Arabia, Kingdom of Senegal, Republic of Serbia and Montenegro Seychelles, Republic of Sierra Leone, Republic of Singapore, Republic of Slovakia (Slovak Republic) Slovenia Solomon Islands Somalia, Somali Republic South Africa, Republic of South Georgia and the South Sandwich Islands Spain, Spanish State Sri Lanka, Democratic Socialist Republic of St. Helena St. Kitts and Nevis St. Lucia St. Pierre and Miquelon St. Vincent and the Grenadines Sudan, Democratic Republic of the Suriname, Republic of Svalbard & Jan Mayen Islands Swaziland, Kingdom of Sweden, Kingdom of Switzerland, Swiss Confederation Syrian Arab Republic Taiwan, Province of China Tajikistan Tanzania, United Republic of Thailand, Kingdom of Timor-Leste, Democratic Republic of Togo, Togolese Republic Tokelau (Tokelau Islands) Tonga, Kingdom of Trinidad and Tobago, Republic of Tunisia, Republic of Turkey, Republic of Turkmenistan Turks and Caicos Islands Tuvalu Uganda, Republic of Ukraine United Arab Emirates United Kingdom of Great Britain & N. Ireland Uruguay, Eastern Republic of Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Viet Nam, Socialist Republic of Wallis and Futuna Islands Western Sahara Yemen Zambia, Republic of Zimbabwe

Go here to read the rest:
Cell Therapy (Differentiated Cell and Stem Cell) Market Research Report 2022 - Global Forecast to 2027: Investments Help Fuel a Surge in Biotech...

Stem Cell Alopecia Treatment Market Size, Trends and Forecast to 2029 | APEX Biologix, Belgravia Center, RepliCel, Riken Research Institute, Kerastem,…

New Jersey, United States The Stem Cell Alopecia Treatment Marketreport includes the upcoming challenges and opportunities in the market. It ensures a strengthened position in the market and a growing product portfolio by providing all the important details related to the market growth. It reveals some of the key insights and focuses on the impact of the COVID-19 crisis on different sectors of the economy. Identifying key business areas is the most important factor to improve those areas and generate greater profits. This vivid market research provides an in-depth understanding of how new product offerings can fit into the marketplace. It acts as the best guide and plays the leading role in almost all phases of the business cycle. It also becomes easy to target customers effectively to launch new products easily. This Stem Cell Alopecia Treatment market reports that another key focus is to provide manufacturing solutions at all provincial and global levels.

A comprehensive overview of market conditions and various business-related elements are covered in this Stem Cell Alopecia Treatment market research report. It enables business players to reach target groups and provides all the important details about customers and competitors. Quantitative research methods are used to conduct this market research to provide accurate market data and problem-solving. The Stem Cell Alopecia Treatment Market report helps to identify the major regions such as Asia Pacific, North America, Europe, Middle East, Africa, and Latin America where new players and merchants can expand their business. Additionally, it performs in-depth analysis and provides market size, market dynamics, and market share.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @https://www.verifiedmarketresearch.com/download-sample/?rid=15102

Also, the market share of each industry over the forecast period is discussed. This market report also provides information on industry dynamics, market share, growth prospects, and challenges. It also conducts market research to determine the growth models, approaches, and techniques used by key players. The most important statistics in the industry trends report provide the ideal reference for companies. Besides company profile, capacity, production rate, value, and product specifications, the report covers some other important parameters.

Key Players Mentioned in the Stem Cell Alopecia Treatment Market Research Report:

APEX Biologix, Belgravia Center, RepliCel, Riken Research Institute, Kerastem, Sanford Burnham Prebys Medical Discovery Institute.

Stem Cell Alopecia TreatmentMarket Segmentation:

Stem Cell Alopecia Treatment Market, By Indication

Male Pattern Baldness Female Pattern Baldness Others

Get a Discount On The Purchase Of This Report @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=15102

Stem Cell Alopecia Treatment Market Report Scope

Key questions answered in the report:

1. Which are the five top players of the Stem Cell Alopecia Treatment market?

2. How will the Stem Cell Alopecia Treatment market change in the next five years?

3. Which product and application will take a lions share of the Stem Cell Alopecia Treatment market?

4. What are the drivers and restraints of the Stem Cell Alopecia Treatment market?

5. Which regional market will show the highest growth?

6. What will be the CAGR and size of the Stem Cell Alopecia Treatment market throughout the forecast period?

For More Information or Query or Customization Before Buying, Visit @ https://www.verifiedmarketresearch.com/product/stem-cell-alopecia-treatment-market/

Visualize Stem Cell Alopecia Treatment Market using Verified Market Intelligence:-

Verified Market Intelligence is our BI-enabled platform for narrative storytelling of this market. VMI offers in-depth forecasted trends and accurate Insights on over 20,000+ emerging & niche markets, helping you make critical revenue-impacting decisions for a brilliant future.

VMI provides a holistic overview and global competitive landscape with respect to Region, Country, and Segment, and Key players of your market. Present your Market Report & findings with an inbuilt presentation feature saving over 70% of your time and resources for Investor, Sales & Marketing, R&D, and Product Development pitches. VMI enables data delivery In Excel and Interactive PDF formats with over 15+ Key Market Indicators for your market.

Visualize Stem Cell Alopecia Treatment Market using VMI @ https://www.verifiedmarketresearch.com/vmintelligence/

About Us: Verified Market Research

Verified Market Research is a leading Global Research and Consulting firm that has been providing advanced analytical research solutions, custom consulting and in-depth data analysis for 10+ years to individuals and companies alike that are looking for accurate, reliable and up to date research data and technical consulting. We offer insights into strategic and growth analyses, Data necessary to achieve corporate goals and help make critical revenue decisions.

Our research studies help our clients make superior data-driven decisions, understand market forecast, capitalize on future opportunities and optimize efficiency by working as their partner to deliver accurate and valuable information. The industries we cover span over a large spectrum including Technology, Chemicals, Manufacturing, Energy, Food and Beverages, Automotive, Robotics, Packaging, Construction, Mining & Gas. Etc.

We, at Verified Market Research, assist in understanding holistic market indicating factors and most current and future market trends. Our analysts, with their high expertise in data gathering and governance, utilize industry techniques to collate and examine data at all stages. They are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research.

Having serviced over 5000+ clients, we have provided reliable market research services to more than 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi. We have co-consulted with some of the worlds leading consulting firms like McKinsey & Company, Boston Consulting Group, Bain and Company for custom research and consulting projects for businesses worldwide.

Contact us:

Mr. Edwyne Fernandes

Verified Market Research

US: +1 (650)-781-4080 UK: +44 (753)-715-0008 APAC: +61 (488)-85-9400 US Toll-Free: +1 (800)-782-1768

Email: sales@verifiedmarketresearch.com

Website:- https://www.verifiedmarketresearch.com/

See more here:
Stem Cell Alopecia Treatment Market Size, Trends and Forecast to 2029 | APEX Biologix, Belgravia Center, RepliCel, Riken Research Institute, Kerastem,...

The American Academy of Stem Cell Physicians Adds Three Workshops to the June 17-19, 2022 Conference – StreetInsider.com

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

MIAMI, May 24, 2022 (GLOBE NEWSWIRE) -- The American Academy of Stem Cell Physicians has added three new workshops to its long-awaited conference this June 17-19, 2022. The hands-on workshops will be led by industry leaders in regenerative medicine. The workshops will be on intradiscal injections, bone marrow aspiration and muscular-skeleton ultrasound techniques. Beyond these educational workshops, The American Academy of Stem Cell Physicians is also presenting a great lineup of acclaimed regenerative medicine leaders discussing what's new in regenerative medicine. This conference is not to be missed.

Dr. Joseph Purita, a pioneer in the use of regenerative cell and PRP therapy for orthopedic conditions, graduated from Georgetown University Medical School and served his surgical internship at the University of Florida Medical Center. Dr. Purita is an instructor and proctor of surgeons in the use of lasers in arthroscopic and orthopedic surgery at a variety of area hospitals. At The American Academy of Stem Cell Physicians, Dr. Purita will lead a workshop on bone marrow aspiration.

Dr. Warren J. Bleiweiss, a guest speaker for AASCP and the American Academy of Stem Cell Physicians' first Fellow graduate, will provide a talk on his innovative regenerative medicine treatments. Dr. Bleiweiss is a national leader in the use of ozone injection treatments for herniated discs, joint and muscle pain, and injuries. He pioneered the outpatient oxygen-ozone disc injection procedure in the United States and remains a leading expert in North America in treating disc herniations with ozone injections without surgery or medication.

The American Academy of Stem Cell Physicians invites you to learn more about Intra Discal PRP injections. Dr. Bleiweiss said, "I am looking forward to discussing all the new advancements in the Regenerative field for 2022 at this year's workshop."

Dr. Kim attended college at Cornell University in NY and received his medical degree from RutgersNew Jersey Medical School. The President of The American Academy of Stem Cell Physicians, Dr. Sunny Kim is also thefounder and President of Progressive Rehabilitation Medicine, whose mission is offering advanced non-surgical pain management solutions. Dr. Kim's workshop is on advanced muscular-skeletal ultrasound diagnostic and injection techniques.

The spokesman for the AASCP, Dr. AJFarshchian,said earlier: "The American Academy of Stem Cell Physicians is a group of physicians, scientists and researchers who collectively represent the most authoritativenon-federal group advocating for guidelines and education on stem cell therapy and regenerative medicine. The AASCP is involved directly with other authorities within the field and seeks only to bring knowledge and awareness for the ever-growing regenerative medicine industry." Dr. Farshchian, a pioneer in regenerative medicine, will offer a workshop on neurogenesis.

AASCP is hosting their medical conference in Miami on June 17-19, 2022. The conference is taking place at the downtown MiamiHyatt Regency, located at 400 SE 2nd Ave., Miami, FL 33131.Becauseof limited seating, we encourage everyone to please RSVP atwww.aascp.net andto register. Registrations are going fast, please register today.

The American Academy of Stem Cell Physicians (AASCP) is an organization created to advance research and the development of therapeutics in regenerative medicine, including diagnosis, treatmentand prevention of disease related to or occurring within the human body. Secondarily, the AASCP aims to serve as an educational resource for physicians, scientistsand the public in diseases that can be caused by physiological dysfunction that areameliorableto medical treatment.

For further information, please contact WilsonDemenessez or Luana Ingrid at AASCP 305-891-4686, and you can also visit us at http://www.aascp.net.

Related Images

Image 1

This content was issued through the press release distribution service at Newswire.com.

Featured Image for The American Academy of Stem Cell Physicians

Featured Image for The American Academy of Stem Cell Physicians

Go here to see the original:
The American Academy of Stem Cell Physicians Adds Three Workshops to the June 17-19, 2022 Conference - StreetInsider.com

Global Heart Failure Pipeline Market Research Report 2022: Comprehensive Insights About 90+ Companies and 90+ Pipeline Drugs – ResearchAndMarkets.com…

DUBLIN--(BUSINESS WIRE)--The "Heart Failure - Pipeline Insight" clinical trials has been added to ResearchAndMarkets.com's offering.

This "Heart Failure - Pipeline Insight, 2022" report provides comprehensive insights about 90+ companies and 90+ pipeline drugs in Heart Failure pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

"Heart Failure - Pipeline Insight, 2022" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Heart Failure pipeline landscape is provided which includes the disease overview and Heart Failure treatment guidelines.

The assessment part of the report embraces, in depth Heart Failure commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

Heart Failure Emerging Drugs

Tirzepatide: Eli Lilly and Company

Tirzepatide is a once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that integrates the actions of both incretins into a single novel molecule. GIP is a hormone that may complement the effects of GLP-1. In preclinical models, GIP has been shown to decrease food intake and increase energy expenditure therefore resulting in weight reductions, and when combined with a GLP-1 receptor agonist, may result in greater effects on glucose and body weight. Tirzepatide is in phase 3 development for chronic weight management and heart failure with preserved ejection fraction (HFpEF). It is also being studied as a potential treatment for non-alcoholic steatohepatitis (NASH). Both the FDA and EMA have accepted Eli Lilly's marketing approval applications for its type 2 diabetes treatment, tirzepatide.

Finerenone (BAY94-8862): Bayer

Finerenone (BAY 94-8862) is an investigational novel, non-steroidal, selective mineralocorticoid receptor antagonist (MRA) that has been shown to block the harmful effects of the overactivated mineralocorticoid receptor (MR) system. MR overactivation is a major driver of heart and kidney damage. Current steroidal MRAs on the market have proven to be effective in reducing cardiovascular mortality in patients suffering from heart failure with reduced ejection fraction (HFrEF). However, they are often underutilized due to the incidence of hyperkalemia, renal dysfunction, and anti-androgenic/ progestogenic side effects.

CardiAMP Cell Therapy: BioCardia

CardiAMP Cell Therapy uses a patient's own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure to potentially stimulate the body's natural healing response. The CardiAMP Cell Therapy Heart Failure Trial is the first multicenter clinical trial of an autologous cell therapy to prospectively screen for cell therapeutic potency in order to improve patient outcomes. CardiAMP Cell Therapy incorporates three proprietary elements not previously utilized in investigational cardiac cell therapy, which the company believes improves the probability of success of the treatment: a pre-procedural diagnostic for patient selection, a high target dosage of cells, and a proprietary delivery system that has been shown to be safer than other intramyocardial delivery systems and more successful for enhancing cell retention.

Rexlemestrocel-L (Revascor): Mesoblast

Revascor consists of 150 million mesenchymal precursor cells (MPCs) administered by direct injection into the heart muscle in patients suffering from CHF and progressive loss of heart function. MPCs release a range of factors when triggered by specific receptor-ligand interactions within damaged tissue. Based on preclinical data, it is believed that these factors induce functional cardiac recovery by simultaneous activation of multiple pathways, including induction of endogenous vascular network formation, reduction in harmful inflammation, reduction in cardiac scarring and fibrosis, and regeneration of heart muscle through activation of tissue precursors.

BMS-986231: Bristol-Myers Squibb

Cimlanod (development codes CXL-1427 and BMS-986231) is an experimental drug for the treatment of acute decompensated heart failure. HNO gas (nitroxyl) is a chemical sibling of nitric oxide. Although nitric oxide and HNO appear to be closely related chemically, the physiological effects and biologic mechanisms of HNO and nitric oxide action are distinct. The biologic effects of HNO are mediated by direct post-translational modification of thiol residues in target proteins, including SERCA2a, phospholamban, the ryanodine receptor, and myofilament proteins in cardiomyocytes. In vitro, HNO increases the efficiency of calcium cycling and improves myofilament calcium sensitivity, which enhances myocardial contraction and relaxation. HNO also mediates peripheral vasodilation through endothelial soluble guanylate cyclase. HNO does not induce tachyphylaxis in peripheral vessels, unlike nitric oxide.

Elamipretide: Stealth BioTherapeutics

Elamipretide (MTP-131, Bendavia) is a novel tetra-peptide that targets mitochondrial dysfunction in energydepleted myocytes. Elamipretide crosses the outer membrane of the mitochondria and associates itself with cardiolipin, which is a phospholipid expressed only in the inner membrane of mitochondria. Cardiolipin has an integral role in mitochondrial stability and organization of respiratory complexes into super complexes for oxidative phosphorylation.Thus, elamipretide helps to enhance ATP synthesis in multiple organs of the body. Elamipretide has been shown to improve left ventricular ejection fraction (LVEF), LV end diastolic pressure, cardiac hypertrophy, myocardial fibrosis, and myocardial ATP synthesis in both animal models and humans.

FA relaxin: Bristol Myers Squibb

BMS-986259 is a next-generation version of Relaxin that is enabled with our technology and currently in Phase 1 clinical trials for ADHF. Relaxin, a peptide hormone, has been reported to reduce fibrosis in the multiple organs and to exert cardioprotective effects in preclinical studies. However, the therapeutic potential of Relaxin has been partially limited by its short half-life in humans. BMS-986259 has exhibited a prolonged half-life and therefore has the potential to enhance clinical benefit as a novel therapeutic for ADHF.

Key Players

Key Products

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/soc45u

Read more:
Global Heart Failure Pipeline Market Research Report 2022: Comprehensive Insights About 90+ Companies and 90+ Pipeline Drugs - ResearchAndMarkets.com...

Characteristics of anti-CLL1 based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety…

Abstract: C-type lectin like molecule-1 (CLL1) is preferentially expressed on acute myeloid leukemia (AML) stem cells and AML blasts, and can be considered as AML-associated antigen. Anti-CLL1-based CAR-T cells exhibited effective tumor killing capacity in vitro and in AML-bearing mouse model. In this report, eight children with relapsed or refractory AML (R/R-AML) were recruited for a phase 1/2 clinical trial of autologous anti-CLL1 CAR-T cell immunotherapy. The objectives of this clinical trial were to evaluate the safety and the anti-AML responses after CLL1-CAR-T cell treatment, with long-term prognosis within those patients who did not receive allogeneic hematopoietic stem cells transplantation (allo-HSCT) as an additional aim. These R/R-AML patients received one dose of autologous CLL1-CAR-T cells after lymphodepletion conditioning. Grade 34 hematologic adverse events were observed post CAR-T cell infusion. Meanwhile, grade 12 cytokine release syndrome (CRS) was observed but without any lethal events. 4 out of 8 AML patients achieved incomplete remission (CRi) and minimal residual disease (MRD) negativity, 2 patients with CRi but MRD positivity, and 2 patients with decreased AML burden and CLL1 positive AML blast clearance. These results suggested that anti-CLL1-based CAR-T cell immunotherapy can be considered as a well-tolerated and effective option for treating children with R/R-AML.

See the article here:
Characteristics of anti-CLL1 based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety...

Stem Cell Therapy Market 2022 Growing with Major Eminent Key Players Anterogen Co., Ltd., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc. and Pharmicell…

The global Fluoropolymer Films Market study intends to deliver a thorough understanding of the market situation in the present, past along with future projections and market estimations framed based on evidential data provided by marketers. This set of data includes the market size and volume of the Global Fluoropolymer Films Market with respect to current market dynamics and the anticipated business size during the forecast graphically represented. Essential data regarding the cost-structure, supply chain and revenue is portrayed as a whole and with granular classification categorizing the Global Fluoropolymer Films Market into business level, industrial level and regional level defining the business growth of the Global Fluoropolymer Films Market in future.

Additionally, the supplies ideal little company options to the market. The Fluoropolymer Films report highlights the contemporary trends, improvements, demanding little business opportunities, along with other essential information of the net wide Fluoropolymer Films marketplace. Requirement ratio as well as the development of innovative technologies are a few the essential elements thats frequently discussed in the net Fluoropolymer Films marketplace listing.

Free Sample Report + All Related Graphs & Charts @ https://www.adroitmarketresearch.com/contacts/request-sample/1524?utm_source=PT

Leading players of Fluoropolymer Films Market including:

The Chemours Company, 3M, Saint-Gobain, Nitto Denko, Honeywell International, Daikin, Rogers Corporation, DUNMORE, AGC Chemicals, Guarniflon, Textiles Coated International

Fluoropolymer Films Market Analysis is a top-notch professionally designed and employed synopsis of this international industry that encloses substantial details on drivers and restraints analytics, inclusive of different market opportunities and challenges which are most likely to influence general growth situation pertaining to international Fluoropolymer Films marketplace. The report hooks significant developments on regional growth prospects, but before exactly the very same, the report incorporates flexible information on Fluoropolymer Films market segmentation that uniquely identifies application and type as important growth segments and components.

Thorough evaluation of the important players who function from the Fluoropolymer Films market area together with their placement in addition to contribution to the market, their investment portfolio in addition to some other insights is emphasized in the study record. Whats more, the report includes recent upgrades, Fluoropolymer Films market asks and critical business methods that that assist the business together with the companies operating inside. Likewise, the record provides thorough analysis of their new mergers, investors, stakeholders and acquisitions who will have enormous effect on the Fluoropolymer Films industry space in the next several years.

The Fluoropolymer Films analysis is used in the timeline forecast to estimate the accurate market share. Market revenue forecasts are provided for each geographic region in the Fluoropolymer Films research report. An overview of the industrys growth opportunities, emerging innovations focused on creative business models, a range of value-added goods, and the competitive context of the competition that can fuel market growth are also included in the report. Similarly, the report provides the most up-to-date forecasts of global demand for the next five years.

Fluoropolymer Films market Segmentation by Type:

Polytetrafluoroethylene (PTFE) films Polyvinylidene fluoride (PVDF) films Fluorinated Ethylene Propylene (FEP) films Perfluoroalkoxy Polymer (PFA) films Ethylene Tetrafluoroethylene (ETFE) films Others

Fluoropolymer Films market Segmentation by Application:

Electrical & Electronics Industrial Automotive & Aerospace Medical & Pharmaceutical Consumer Products Others

Predominant Questions Answered in This Report Are:

1. Which segments will perform well in the Fluoropolymer Films market over the forecasted years? 2. In which markets companies should authorize their presence? 3. What are the forecasted growth rates for the market? 4. What are the long-lasting defects of the industry? 5. How share market changes their values by different manufacturing brands? 6. What are the qualities and shortcomings of the key players? 7. What are the major end results and effects of the five strengths study of industry?

Table of Content:

1 Scope of the Report 1.1 Market Introduction 1.2 Research Objectives 1.3 Years Considered 1.4 Market Research Methodology 1.5 Economic Indicators 1.6 Currency Considered 2 Executive Summary 3 Global Fluoropolymer Films by Players 4 Fluoropolymer Films by Regions 4.1 Fluoropolymer Films Market Size by Regions 4.2 Americas Fluoropolymer Films Market Size Growth 4.3 APAC Fluoropolymer Films Market Size Growth 4.4 Europe Fluoropolymer Films Market Size Growth 4.5 Middle East & Africa Fluoropolymer Films Market Size Growth 5 Americas 6 APAC 7 Europe 8 Middle East & Africa 9 Market Drivers, Challenges and Trends 9.1 Market Drivers and Impact 9.1.1 Growing Demand from Key Regions 9.1.2 Growing Demand from Key Applications and Potential Industries 9.2 Market Challenges and Impact 9.3 Market Trends 10 Global Fluoropolymer Films Market Forecast 11 Key Players Analysis 12 Research Findings and Conclusion

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/1524?utm_source=PT

ABOUT US:

Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

CONTACT US:

Ryan Johnson Account Manager Global 3131 McKinney Ave Ste 600, Dallas, TX 75204, U.S.A Phone No.: USA: +1.210.667.2421/ +91 9665341414

More:
Stem Cell Therapy Market 2022 Growing with Major Eminent Key Players Anterogen Co., Ltd., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc. and Pharmicell...

InnoCare Announces Approval to Conduct a Phase II Clinical Trial of Tafasitamab in Combination with Lenalidomide in China – Business Wire

BEIJING--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969) announced today that it has received approval to conduct a single-arm, open-label, multicenter phase II clinical trial evaluating the safety and efficacy of tafasitamab in combination with lenalidomide by Chinas National Medical Products Administration (NMPA) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplantation (ASCT).

Tafasitamab is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, which is conditionally approved by both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) in combination with lenalidomide for the treatment of adult patients with relapsed or refractory DLBCL who are not eligible for ASCT. Tafasitimab is not approved by the NMPA for any indication.

Dr. Jasmine Cui, Co-founder, Chairwoman and CEO of InnoCare, said, We will make every effort to accelerate the clinical development of tafasitamab in combination with lenalidomide to help address the unmet needs of DLBCL patients in China.

Tafasitamab (Monjuvi) is co-commercialized by Incyte and MorphoSys in the United States and by Incyte under the brand name Minjuvi in the EU. As part of its agreement with MorphoSys, Incyte received exclusive commercialization rights for tafasitamab outside the United States, and in August 2021, Incyte entered into a collaboration and license agreement with InnoCare for the development and exclusive commercialization of tafasitamab in hematology and oncology in Greater China.

DLBCL is the most common type of non-Hodgkin lymphoma (NHL), and its incidence accounts for 31% to 34% of NHL globallyi. In China, DLBCL accounts for 45.8% of all NHLsi.

About Tafasitamab

Tafasitamab is a humanized monoclonal antibody targeting CD19.

In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc.

Tafasitamab incorporates an XmAb engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism including Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cellular Phagocytosis (ADCP).

In the United States, Monjuvi (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration in combination with lenalidomide for the treatment of adult patients with relapsed or refractory DLBCL not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for ASCT. This indication is approved under accelerated approval based on overall response rate. Full approval for this indication may be contingent upon results in a confirmatory trial(s).

In Europe, Minjuvi (tafasitamab) received conditional approval, in combination with lenalidomide, followed by Minjuvi monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT).

Tafasitamab is being clinically investigated as a therapeutic option in B-cell malignancies in several ongoing combination trials.

Tafasitamab is not approved for use in China except for in the Boao Lecheng International Medical Tourism Pilot Zone through an early access program.

Minjuvi and Monjuvi are registered trademarks of MorphoSys AG. Tafasitamab is co-marketed by Incyte and MorphoSys under the brand name Monjuvi in the U.S. and marketed by Incyte under the brand name Minjuvi in the EU. As part of its agreement with MorphoSys, Incyte received exclusive commercialization rights for tafasitamab outside the United States, and in August 2021, Incyte entered into a collaboration and license agreement with InnoCare for the development and exclusive commercialization of tafasitamab in hematology and oncology in Greater China.

XmAb is a registered trademark of Xencor, Inc.

About InnoCare

InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases. We strategically focus on lymphoma, solid tumors, and autoimmune diseases with high unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and United States.

InnoCare Forward-looking Statements

This report contains the disclosure of some forward-looking statements. Except for statements of facts, all other statements can be regarded as forward-looking statements, that is, about our or our management's intentions, plans, beliefs, or expectations that will or may occur in the future. Such statements are assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future development and other related factors. This forward-looking statement does not guarantee future performance, and actual results, development and business decisions may not match the expectations of the forward-looking statement. Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short-term and long-term performance.

i Hematology Branch of Chinese Medical Association2013

Go here to read the rest:
InnoCare Announces Approval to Conduct a Phase II Clinical Trial of Tafasitamab in Combination with Lenalidomide in China - Business Wire